Flagship startup Omega takes lead 'epigenomic controller' candidate closer to the clinic with new $126M round
In its quest to drug the undruggable, Flagship Pioneering startup Omega Therapeutics is chasing a moonshot with “epigenomic controllers” to get all of the benefits of gene editing without the actual editing. That’s a tall task to craft a new class of therapeutics, but investors are certainly showing interest.
Omega plans to advance its lead candidate for the c-myc oncogene into human testing and establish a manufacturing footprint with proceeds from a $126 million Series C the biotech closed Tuesday.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.